Assessment of Potential Interactions Between Cocaine and RPR 102681 - 1 - Full Text View

Assessment of Potential Interactions Between Cocaine and RPR 102681 - 1

This study is ongoing, but not recruiting participants.

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00067535

Purpose

The purpose of this study is to assess Potential Interactions Between iv Cocaine and RPR 102681

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Cocaine-Related Disorders	Phase I

Drug Information available for:

8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety Study

Official Title:	Potential Interactions Between IV Cocaine and RPR 102681

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Safety

Estimated Enrollment:	16
Study Start Date:	June 2003

Detailed Description:

Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Includes but is not limited to:

Non-treatment seekers
DSM-IV criteria for cocaine abuse or dependence
Ability to verbalize understanding of consent form and provide written informed consent and verbalize willingness to complete study procedures; be able to comply with protocol requirements

Exclusion Criteria:

Please contact site for more information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00067535

Locations


United States, Maryland
	Uniformed Services University of Health Science
	Bethesda, Maryland, United States, 20814 4799

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators


Principal Investigator:	Louis Cantilena, M.D.	Uniformed Services University of Health Science

More Information

Study ID Numbers:	NIDA-CPU-0003-1
First Received:	August 21, 2003
Last Updated:	October 23, 2007
ClinicalTrials.gov Identifier:	NCT00067535
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Cocaine-Related Disorders

Dopamine

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

Cocaine

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors

Neurotransmitter Agents

Neurotransmitter Uptake Inhibitors

Molecular Mechanisms of Pharmacological Action

Physiological Effects of Drugs

Anesthetics

Central Nervous System Depressants

Cardiovascular Agents

Pharmacologic Actions

Anesthetics, Local

Sensory System Agents

Therapeutic Uses

Vasoconstrictor Agents

Dopamine Agents

Peripheral Nervous System Agents

Central Nervous System Agents

ClinicalTrials.gov processed this record on November 30, 2008